Drug Profile
DS 7309
Alternative Names: DS7309Latest Information Update: 21 Jan 2015
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 21 Jan 2015 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 30 Sep 2013 Daiichi Sankyo initiates enrolment in a phase I trial for Type-2 diabetes mellitus in USA (NCT01956305)
- 30 Sep 2011 Daiichi Sankyo completes a phase I trial in Type-2 diabetes mellitus in USA (NCT01862939)